Examples include CUDC-101, which inhibits HDAC1, epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2) and has been effective in preclinical models of lymphoma and solid tumors, and CUDC-907, which has demonstrated a significant response rate in relapsed/refractory diffuse large B-cell lymphoma patients [61, 62]. This evidence concerns the gene ERBB2 and lymphoma.